It should be noted that a preliminary experiment was performed with a small number of Luc+ H1975 tumor-bearing mice but no therapeutic effect was observed with afatinib combined to osimertinib (S13 Fig; n = 2). Interestingly, we also assessed the effect of the MEK 1/2 inhibitor selumetinib (AZD6244, Astrazeneca, Cambridge, UK) and of the HDAC inhibitor simvastatin (S14 Fig). Here, MAP2K1 is linked to neoplasm.